Is Compounded Tirzepatide Still Legal? What the FDA Actually Says

Search "compounded tirzepatide" and you will find dozens of telehealth companies still selling it, and dozens of blog posts confidently declaring it legal, illegal, or "in a gray area." Almost none of them cite anything more specific than "the FDA." The FDA, as it happens, has been extremely specific — it has kept a single running timeline on its own site since 2024, updated as recently as April 2026, and most of what gets written about this question ignores it entirely.

Here is what that timeline actually says, with dates.

The shortage that made compounding possible

Compounding pharmacies are allowed to make a copy of a patented, FDA-approved drug under narrow legal exemptions — sections 503A and 503B of the Food, Drug and Cosmetic Act — and one of the biggest exemptions is a drug shortage. When a brand-name drug is officially listed as in shortage, both 503A pharmacies (compounding for a named, individual patient) and 503B outsourcing facilities (compounding in batches) get room to fill the gap without being treated as making an illegal copy of a commercial product¹.

Tirzepatide — sold under the brand names Mounjaro and Zepbound — had been on that shortage list since 2022, driven by demand that outstripped Eli Lilly's manufacturing capacity. That shortage is the entire reason a compounded-tirzepatide industry exists.

The FDA has now said, twice, that the shortage is over

• •October 2, 2024 — FDA determined the tirzepatide injection shortage was resolved, based on the manufacturer's confirmed ability to meet national demand¹.
• •October 22, 2024 — that determination was legally remanded back to the FDA for reevaluation, as part of ongoing litigation (Outsourcing Facilities Association v. FDA).
• •December 19, 2024 — FDA re-evaluated and reached the same conclusion: the shortage is resolved. To soften the landing, the agency gave 503A pharmacies until February 18, 2025, and 503B outsourcing facilities until March 19, 2025, before it would start treating shortage-based compounding as a violation¹.
• •March 5, 2025 — a federal district court denied a preliminary injunction in that same litigation. Per FDA's own update, that meant 503A enforcement discretion "has ended" immediately for state-licensed pharmacies and physicians; the 503B grace window ran through March 19, 2025¹.

Semaglutide (Ozempic/Wegovy) went through the identical sequence on a roughly two-month delay: shortage declared resolved February 21, 2025, 503A discretion ending April 22, 2025, and 503B discretion ending May 22, 2025 after the same court denied a follow-up injunction motion on April 24, 2025¹.

What "the shortage is over" actually closes off

This is the part most secondary coverage skips. A 503A pharmacy is barred from compounding a drug that is "essentially a copy" of a commercially available product — and once the FDA calls a shortage resolved, tirzepatide counts as commercially available again. FDA's own compounding guidance treats a compounded drug as "essentially a copy" when it has the same active ingredient, in a similar or substitutable strength, given the same way, as the approved product — unless a prescriber documents that a specific change (a different dose the manufacturer doesn't make, for example) is clinically necessary for that individual patient¹.

503B outsourcing facilities face a separate, narrower gate: they can only compound from a bulk drug substance if that substance is either on FDA's "503B bulks list," or the finished drug is on the shortage list at the time of compounding. As of FDA's most recent update, tirzepatide and semaglutide are on neither list¹ — which means the shortage-based path is closed for 503B facilities too, not just 503A pharmacies.

FDA does carve out one narrow allowance on the 503A side: it says it does not currently intend to act against a pharmacy that fills four or fewer prescriptions of an essentially-a-copy compounded drug in a calendar month¹. That is a small-scale, patient-specific safety valve — not a basis for a nationwide telehealth subscription business.

So what does that leave, legally, in 2026?

Reading the FDA's own conditions rather than a summary of them, compounded tirzepatide remains on solid legal footing in a few specific situations:

• •A prescriber documents an individualized reason a specific patient needs a dose or formulation the commercial product doesn't offer (the FDA-approved product comes in fixed 2.5-15mg pens; a documented, patient-specific dose outside that range is the clearest example).
• •A patient has a verified allergy or intolerance to an inactive ingredient in the commercial product.
• •A pharmacy stays under the ≤4-prescriptions-per-month threshold for compounding that would otherwise count as "essentially a copy."

What it does not cover, per the agency's own stated position, is bulk 503A or 503B compounding of tirzepatide simply because it is cheaper than the branded product, marketed at telehealth-subscription scale, with no individualized medical justification tied to a named patient.

Why this matters when you're comparing providers

None of this makes every compounding pharmacy dispensing tirzepatide "illegal" — a provider genuinely operating inside one of the exceptions above is on solid ground, and plenty of legitimate 503A pharmacies do exactly that. What it means is that "compounded" and "cheap" are no longer, by themselves, evidence that a provider found a clever workaround — the workaround the whole industry ran on for two years has been legally narrowed since December 2024, in writing, by the agency that enforces it. A provider whose intake never asks why a compounded dose is medically necessary for you, specifically, is not obviously operating inside the exception FDA actually left open.

That is a pharmacy-sourcing question, not a medical one, and it is exactly why our tirzepatide provider comparison reads pharmacy disclosures directly off each provider's own site rather than assuming "compounded" means the same thing at every company.

How the providers we've reviewed handle it

None of this determination is specific to any one company — every telehealth provider selling compounded tirzepatide operates under the same narrowed rules above. What differs is how openly each one discloses the pharmacy and compounding details that let a reader judge that for themselves:

• •Precision Telemed's write-up covers the only provider on our board that names both a specific pharmacy and a 503A category on its own product pages.
• •Found's review covers the one other provider stating a 503A category in its own words — though unlike Precision Telemed, it names no specific pharmacy vendor.
• •The PlexusDx review covers the only one of the six to state plainly, in its own words, that its compounded medications are not FDA-approved.
• •CoreAge Rx, reviewed here, advertises a low starting price on our board but names no pharmacy and states no facility category.
• •yourEra's page covers a provider running tirzepatide and several other compounds off one page with no pharmacy named either.
• •Henry Meds' review covers a provider whose own pages disagree with each other on which federal pharmacy category applies — its product page hedges between 503A and 503B while its Terms of Service state 503A alone.

This is a different question from the shortage-and-compounding-law question above, and it is worth reading separately — a company can be fully compliant with FDA's compounding rules and still tell you very little about who actually fills the prescription. Sermorelin and the other growth-hormone secretagogues run under a related but distinct compounding framework (they were never on FDA's GLP-1 shortage list); see what we found ranking that category if that is the category you are researching. Once a prescriber has actually given you a compounded tirzepatide dose in milligrams, our reconstitution calculator converts that into the exact syringe volume and insulin-syringe units it corresponds to — arithmetic on the number your prescriber gave you, not a suggestion of what that number should be.